曲尼司特通过阻断RelA/p65活性诱导子宫肌瘤平滑肌细胞miR-200c表达
该实验研究探讨曲尼司特诱导子宫肌瘤平滑肌细胞(LSMC)中miR-200c表达的机制。曲尼司特剂量依赖性诱导LSMC和子宫肌层平滑肌细胞(MSMC)中miR-200c,对LSMC作用更强;Bay 117082增强此诱导,siRNA敲低RelA/p65也诱导miR-200c。曲尼司特不影响总RelA/p65蛋白水平,但显著诱导S536磷酸化并降低活性和核转位,ChIP显示减少RelA/p65与miR-200c启动子结合。曲尼司特抑制IL8表达,miR-200c诱导部分介导其对IL8和CDK2的抑制。结论:曲尼司特通过抑制NF-κB信号通路转录机制诱导miR-200c,提示炎症在肌瘤发病中的作用及抗炎药物潜力。
要点
- 曲尼司特剂量依赖性诱导LSMC和MSMC中miR-200c,对LSMC作用更强。
- 曲尼司特通过抑制RelA/p65核转位及启动子结合诱导miR-200c。
- miR-200c部分介导曲尼司特对IL8和CDK2表达的抑制。
核心结论
- 曲尼司特在LSMC中通过抑制NF-κB信号通路的转录机制诱导miR-200c表达。
- 结果提示炎症在子宫肌瘤发病中具有重要意义,抗炎药物可能用于治疗子宫肌瘤。
研究设计与样本
- 实验研究,在学术研究实验室进行。
- 对象为因子宫肌瘤行子宫切除术的女性。
- 干预为阻断RelA/p65。
- 主要结局指标为曲尼司特和阻断RelA/p65对miR-200c表达的影响。
主要发现
- 曲尼司特剂量依赖性诱导LSMC和MSMC中miR-200c,对LSMC作用比MSMC更显著。
- Bay 117082(IκB磷酸化抑制剂)处理LSMC进一步增强曲尼司特对miR-200c的诱导。
- siRNA敲低RelA/p65也诱导LSMC中miR-200c表达。
- 曲尼司特对LSMC总RelA/p65蛋白水平无影响,但显著诱导RelA/p65 S536磷酸化,同时降低其活性及核转位。
- ChIP实验表明曲尼司特降低RelA/p65与miR-200c启动子的结合能力,导致miR-200c诱导。
临床怎么用
- 曲尼司特可能通过诱导miR-200c抑制IL8和CDK2,为子宫肌瘤抗炎治疗提供实验依据。
- 靶向NF-κB信号通路(RelA/p65)可能成为子宫肌瘤治疗策略。
局限性
- 研究为体外实验,结果需进一步体内验证。
- 样本来源为行子宫切除术的女性,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the mechanism by which tranilast induces miR-200c expression in leiomyoma smooth muscle cells (LSMCs). DESIGN: Experimental study. SETTING: Academic research laboratory. PATIENT(S): Women undergoing hysterectomy for leiomyoma. INTERVENTION(S): Blockade of RelA/p65. MAIN OUTCOME MEASURE(S): Effects of tranilast and blockade of RelA/p65 on miR-200c expression. RESULT(S): Tranilast, an inflammation inhibitor, dose-dependently induced miR-200c in LSMCs and myometrium smooth muscle cells (MSMCs), with a more profound effect in LSMCs than in MSMCs. The treatment of LSMCs with Bay 117082, an inhibitor of IκB phosphorylation, further enhanced miR-200c induction by tranilast. The knockdown of RelA/p65 by small interfering RNA also induced miR-200c expression in LSMCs. Although tranilast had no effect on total RelA/p65 protein levels in LSMCs, it significantly induced RelA/p65 phosphorylation at S536 while reducing its activity as well as its nuclear translocation. ChIP assay indicated that tranilast reduces the binding ability of RelA/p65 to miR-200c promoter, resulting in miR-200c induction. Tranilast also inhibited interleukin-8 (IL8) expression in LSMCs. The induction of miR-200c by tranilast partially mediates the inhibitory effect of tranilast on the expression of IL8 and cyclin-dependent kinase 2 in LSMCs. CONCLUSION(S): Induction of miR-200c by tranilast in LSMCs is mediated through a transcriptional mechanism involving inhibition of the nuclear factor κB signaling pathway. These results highlight the significance of inflammation in the pathogenesis of leiomyoma and the potential utility of antiinflammatory drugs for treatment of leiomyomas.
引用
- Chuang TD, Rehan A, Khorram O, et al. Tranilast induces MiR-200c expression through blockade of RelA/p65 activity in leiomyoma smooth muscle cells. Fertil Steril. 2020. PMID: 32199621. doi:10.1016/j.fertnstert.2019.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。